The aim is to review pathophysiological mechanisms and treatment of nocturnal asthma.
Physiologic changes accompanying sleep, as well as the nocturnal phase of circadian rhythms, may have an adverse effect on asthma control. Chronotherapeutic principles, which consider circadian variation in relevant biologic rhythms, may improve asthma outcomes. Administration of long-acting bronchodilators and inhaled corticosteroids which achieve maximum efficacy at night may improve nocturnal asthma. Comorbid conditions that may contribute to nocturnal asthma should be considered. The prevalence of obstructive sleep apnea is greater in a cohort of patients with severe asthma than in moderate asthma and in BMI and age matched nonasthmatic controls, suggesting a link between these diseases. A large trial concluded that esomeprazole did not improve asthma control even with comorbid acid reflux, questioning the importance of acid reflux in asthma. The role of polymorphisms of the β2-adrenergic receptor and their relationship with nocturnal asthma remain controversial.
Sleep is a time of vulnerability to respiratory compromise, especially in asthma patients experiencing nocturnal exacerbations. This asthma phenotype is associated with poorer control, reduced sleep quality, daytime somnolence and increased morbidity and mortality. Nocturnal asthma is a common but under-recognized problem.
Division of Pulmonary, Critical Care and Sleep Medicine, The North Shore-LIJ Health System, Hofstra University School of Medicine, New Hyde Park, New York, USA
Correspondence to Rubin I. Cohen, MD, Division of Pulmonary, Critical Care and Sleep Medicine, The North Shore-LIJ Health System, Hofstra University School of Medicine, 410 Lakeville Road, Suite 107, New Hyde Park, NY 11042, USA. Tel: +1 516 465 5400; fax: +1 516 465 5454; e-mail: email@example.com